Effect of oral administration of pimobendan in cats with heart failure
Effect of oral administration of pimobendan in cats with heart failure
复制标题
DOI：
10.2460/javma.241.1.89
复制
发表时间：
2012-07-01
影响因子：
1.9
通讯作者：
Miller, Matthew W.
中科院分区：
文献类型：
--
作者：
Gordon, Sonya G.;Saunders, Ashley B.;Miller, Matthew W.
目的：探讨口服匹莫本丹对以心脏收缩功能不全为特征的心力衰竭猫的临床和超声心动图指标及存活时间的影响。设计-回顾性队列研究。27只猫(雄性16只，雌性11只)心力衰竭动物，给予匹莫本丹(平均+/-SD剂量，0.26+/-0.08 mg/kg[0.118+/-0.036 mg/lb]，PO，q12h)。治疗过程--病史、实验室结果、诊断影像表现、所接受的治疗、和存活时间是从猫的医疗记录中获得的，这些猫因为心脏病而接受了匹莫本丹的治疗。在可能的情况下，通过电话采访推荐的兽医和主人获得更多的后续信息。结果-所有27只猫的平均+/-SD年龄为8.9+/-5.2岁。所有的猫都接受了几种心脏药物治疗。未分类心肌病11例(41%)，扩张型心肌病8例(30%)，致心律失常性右室心肌病4例(15%)，先天性心脏病3例(11%)，肥厚型心肌病伴局部运动功能减退1例(4%)。所有猫均有室性收缩功能障碍。1只二尖瓣收缩前移的猫在最初服用匹莫本丹后血压严重降低，并被排除在生存分析之外。中位生存期为167天(95%可信区间，32~339天)。结论和临床相关性-吡莫本丹在以各种原因的心脏收缩功能障碍为特征的心力衰竭猫中表现出良好的耐受性。二尖瓣收缩前移的猫在使用匹莫本丹治疗时可能会发生全身性低血压。在推荐用于治疗猫的充血性心力衰竭之前，还需要进行更多的研究来确定匹莫本丹的剂量及其效果。(《兽医杂志》2012；241：89-94)
Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction.Design-Retrospective cohort study.Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean +/- SD dosage, 0.26 +/- 0.08 mg/kg [0.118 +/- 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners.Results-The mean +/- SD age of all 27 cats was 8.9 +/- 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardiomyopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11%]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF. (J Am Vet MEd Assoc 2012;241:89-94)